摘要
目的:分析康艾注射液联合恩替卡韦对乙型肝炎相关性肝癌(HBV-HCC)患者TACE术后生存率的影响及相关影响因素的分析。方法:将已行TACE术治疗的86例HBV-HCC患者随机分为两组,对照组患者43例,给予恩替卡韦治疗;观察组患者43例,给予康艾注射液联合恩替卡韦治疗,均治疗12个月,随访5年。比较两组患者3、5年生存率及无进展生存率,记录并比较两组患者的临床资料,采用Cox多因素分析筛选出有统计学意义的独立危险因素;采用Kaplan-Meier法经临床分期分层后对两组患者的中位生存期、中位无进展生存期进行比较。结果:观察组患者临床分期分层后3、5年生存率及无进展生存率均高于对照组(P<0.05)。单因素分析显示,临床分期、门静脉癌栓、治疗方案是HBV-HCC患者5年生存率的影响因素(P<0.05)。Cox多因素分析显示,临床分期、治疗方案是影响HBV-HCC患者生存率的独立影响因素(P<0.05)。按照临床分期分层,观察组Ⅱ期、Ⅲa期患者的中位生存期均长于对照组(13.9个月vs 7.0个月,6.5个月vs 3.4个月,P<0.05)。观察组Ⅱ期、Ⅲa期患者的中位无进展生存期均长于对照组(10.8个月vs 6.3年,5.1个月vs 2.7个月,P<0.05)。结论:与单纯恩替卡韦治疗相比,康艾注射液联合恩替卡韦治疗可显著提高Ⅱ~Ⅲa期HBV-HCC患者的生存率和生存周期。
Objective:To explore the impact of administering Kangai injections in conjunction with entecavir on the survival rates of patients afflicted with hepatocellular carcinoma associated with hepatitis B(HBV-HCC)following transcatheter arterial chemoembolization(TACE),and to identify the factors that influence this outcome.Methods:86 patients with HBV-HCC who had been treated with TACE in our hospital were randomly divided into two groups.43 patients in the control group were treated with Intecavir,and 43 patients in the observation group were treated with kang'ai injection combined with Entecavir.Both groups were treated for 12 months and followed up for 5 years.The 3 years and 5 years survival rate and progression-free survival rate of the two groups were compared,the clinical data of the two groups were recorded and compared,and the COX multivariate analysis was used to screen out statistically significant independent risk factors.The Kaplan-Meier method was used to stratified the median survival and median progression-free survival of the two groups according to tumor stage.Results:The 3-year,5-year survival rate and progression-free survival rate of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).Univariate analysis showed that clinical stage,portal vein tumor thrombus and treatment plan were the factors affecting the 5-year survival rate of patients with HBV-HCC(P<0.05).COX multivariate analysis showed that clinical stage and treatment plan were independent factors affecting the survival rate of patients with HBV-HCC(P<0.05).Stratified by clinical stage,the median survival time of patients with stageⅡandⅢa in the observation group was longer than that in the control group(13.9 months vs.7.0 months,6.5 months vs.3.4 months,P<0.05).The median progression-free survival of patients with stageⅡand stageⅢa in the observation group was higher than that in the control group(10.8 months vs.6.3 years,5.1 months vs.2.7 months),and the differ
作者
顾树江
陶源
张春铭
盛利
张喆
张永勇
韩呈武
GU Shu-jiang;TAO Yuan;ZHANG Chun-ming(Laboratory Department,Beijing Changping District Hospital of Traditional Chinese Medicine(Beijing 102200),China;不详)
出处
《中西医结合肝病杂志》
CAS
2024年第4期305-309,共5页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
河北省医学科学研究课题计划(No.20211664)。
